Last reviewed · How we verify
NCT06342024
Pistachio Consumption on Inflammatory Markers and Lean Body Mass
NA trial testing Pistachio group in Inflammatory Response in 144 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2026
Quick facts
| Lead sponsor | Virginia Polytechnic Institute and State University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 144 |
| Start date | 20 February 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pistachio group
Conditions studied
- Inflammatory Response — all drugs for Inflammatory Response →
Sponsor
Virginia Polytechnic Institute and State University
Who can join
Adults 40 to 60, any sex, with Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pistachio nuts (Pistacia vera L.) are a nutrient- and energy-dense food, and are a significant source of 15 different micronutrients. In addition to an excellent micronutrient profile, pistachios are a good source of monounsaturated and polyunsaturated fats (linoleic acid, oleic acid, and plant sterols). Pistachios have the lowest amount of total fat, and the highest protein, fiber, and phytosterol content compared to other nuts. They possess a high antioxidant content. Specifically, pistachios have high amounts of lutein, zeaxanthin, and phenolic compounds (e.g., anthocyanins, flavonoids, and proanthocyanidins). These aforementioned compounds are known for their anti-inflammatory effects. Pistachios also have been shown to reduce the risk of cardiovascular disease, metabolic syndrome, and all-cause mortality. The purpose of this study will be to determine the effects of consuming 1.5 ounces of pistachios per day compared to consuming no pistachios per day on inflammatory markers (creatine kinase, C-reactive protein, cortisol, Interleukin-8, tumor necrosis factor-alpha, copper-zinc superoxide dismutase, and glutathione peroxidase concentrations) and lean body mass in women and men, 40 to 60 years of age, who have been recreationally active for at least six months (exercising three to five days per week). It is hypothesized that pistachio consumption will significantly lower inflammatory response and significantly increase lean body mass. This will be a randomized study where participants will first complete a two-week baseline run-in period during which they will consume their typical diet. Following this, participants will be randomized to one of two groups for six months: consuming 1.5 ounces of pistachios per day or a control group (consuming no pistachios). Those consuming pistachios will be in addition to their usual diet. The overall goal of this study is to evaluate the effects of pistachio consumption on inflammatory markers and lean body mass in women and men, 40 to 60 years of age, who exercise three to five days per week. This study could provide a simple, healthy way for recreationally active individuals to decrease inflammation and improve body composition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06342024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Response
Currently open trials in the same condition.
- NCT06450704 — Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders · NA · recruiting
- NCT06519487 — Social Experiences and Demographic Factors in the Regulation of Immune Cells · NA · recruiting
- NCT06434701 — Severe COVID-19 Infection in Children Presenting to EDs in Israel and England · NA · recruiting
- NCT06491966 — Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis · recruiting
- NCT06745102 — Hop Compounds on the Immune System in Overweight People · NA · recruiting
Other Virginia Polytechnic Institute and State University trials
Trials by the same sponsor.
- NCT07521072 — Testing an Intervention for College Students With Food Insecurity and Binge Eating · EARLY_PHASE1 · not yet recruiting
- NCT07042373 — Effects of Tobacco Abuse Liability-dependent Taxes in the ETM · NA · not yet recruiting
- NCT07158749 — Generalized and Domain-Specific Episodic Thinking for Smoking Cessation · NA · not yet recruiting
- NCT07457710 — Remote Haptic Rehabilitation for Parkinson's Disease · NA · not yet recruiting
- NCT05103514 — The Longitudinal Impact of SES and the CNDS on Recovery From SUD · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06342024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia Polytechnic Institute and State University
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06342024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing